Larimar Therapeutics LRMR Stock
1.98 USD
{{ price }}
-10.000001%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
126.78M USD
LOW - HIGH [24H]
1.97
-
2.13 USD
VOLUME [24H]
650.75K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.32 USD
Larimar Therapeutics Price Chart
Larimar Therapeutics LRMR Financial and Trading Overview
| Larimar Therapeutics stock price | 1.98 USD |
| Previous Close | 3.69 USD |
| Open | 3.71 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 900 |
| Day's Range | 3.4 - 3.74 USD |
| 52 Week Range | 1.53 - 6.85 USD |
| Volume | 249.08K USD |
| Avg. Volume | 265.6K USD |
| Market Cap | 147.12M USD |
| Beta (5Y Monthly) | 0.190439 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.32 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.88 USD |
LRMR Valuation Measures
| Enterprise Value | 53.38M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2075474 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3849288 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.527 |
Trading Information
Larimar Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.190439 |
| 52-Week Change | 78.94% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.85 USD |
| 52 Week Low | 1.53 USD |
| 50-Day Moving Average | 4.22 USD |
| 200-Day Moving Average | 4.16 USD |
LRMR Share Statistics
| Avg. Volume (3 month) | 265.6K USD |
| Avg. Daily Volume (10-Days) | 246.98K USD |
| Shares Outstanding | 43.27M |
| Float | 20.75M |
| Short Ratio | 0.55 |
| % Held by Insiders | 1.61% |
| % Held by Institutions | 90.13% |
| Shares Short | 196.99K |
| Short % of Float | 0.77% |
| Short % of Shares Outstanding | 0.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.19% |
| Return on Equity (ttm) | -40.32% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -34962000 USD |
| Net Income Avi to Common (ttm) | -32938000 USD |
| Diluted EPS (ttm) | -1.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 111.52M USD |
| Total Cash Per Share (mrq) | 2.58 USD |
| Total Debt (mrq) | 5.25M USD |
| Total Debt/Equity (mrq) | 4.94 USD |
| Current Ratio (mrq) | 14.165 |
| Book Value Per Share (mrq) | 2.455 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27587000 USD |
| Levered Free Cash Flow (ttm) | -15477500 USD |
Profile of Larimar Therapeutics
| Country | United States |
| State | PA |
| City | Bala Cynwyd |
| Address | Three Bala Plaza East |
| ZIP | 19004 |
| Phone | 844 511 9056 |
| Website | https://www.larimartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Q&A For Larimar Therapeutics Stock
What is a current LRMR stock price?
Larimar Therapeutics LRMR stock price today per share is 1.98 USD.
How to purchase Larimar Therapeutics stock?
You can buy LRMR shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Larimar Therapeutics?
The stock symbol or ticker of Larimar Therapeutics is LRMR.
Which industry does the Larimar Therapeutics company belong to?
The Larimar Therapeutics industry is Biotechnology.
How many shares does Larimar Therapeutics have in circulation?
The max supply of Larimar Therapeutics shares is 64.03M.
What is Larimar Therapeutics Price to Earnings Ratio (PE Ratio)?
Larimar Therapeutics PE Ratio is now.
What was Larimar Therapeutics earnings per share over the trailing 12 months (TTM)?
Larimar Therapeutics EPS is -1.32 USD over the trailing 12 months.
Which sector does the Larimar Therapeutics company belong to?
The Larimar Therapeutics sector is Healthcare.
Larimar Therapeutics LRMR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}